The contract, though sizable, is likely immaterial to CVS’ earnings. But it moves the company in a positive direction as it continues to struggle with recent challenges, an analyst said.

More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and ...

CVS Health Corporation CVS is gaining investor attention as the stock trends higher ahead of its second-quarter earnings ...

This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...

CVS Caremark has removed coverage of Zepbound, a GLP-1 weight-loss drug, citing pricing concerns and shifting payer dynamics ...

Last month, CVS Caremark announced that it had struck a deal to make Novo's Wegovy its primary weight loss drug starting in the second half of the year, which would mean coverage for Lilly's ...

Pharmacy benefit manager CVS Caremark decided to replace Zepbound with Wegovy for use in weight loss starting July 1, despite Zepbound users having more weight loss success.